The Resilient Bull Case for Red Violet (RDVT): From Dip to Violent Snapback
Immersion Investment Partners’ Q2 2025 investor letter cited a 39.1% return in Q2 2025 versus the Russell 2000’s 21.5%. In its Q2 2026 letter, it discussed Red Violet, Inc. (NASDAQ:RDVT), citing a $65.65 close on Aug. 10, 2026 and 52-week gains of 53.78%. It cited Q1 2026 revenue up 17% to $25.8M and said Forewarn’s healthcare entry targets $50M to $75M revenue.
How this was made
The 30-second read
Why it matters
The text argues RDVT’s identity offering is insulated from AI disruption, points to expectation-beating Q2 results and strong April performance, and adds a growth catalyst via Forewarn’s formal entry into healthcare with an immediately addressable revenue range.
Market read
Traders get a bullish, thesis-driven read on RDVT’s AI-resilience and a healthcare expansion angle, but the piece is not a clear new primary disclosure like an earnings release or SEC filing.
What to watch
The article does not quantify margins, backlog, or customer concentration, so the $50M to $75M revenue opportunity for Forewarn may be speculative without corroborating KPIs.
Background
Immersion Investment Partners published its Q2 2025 investor letter and, in its Q2 2026 letter, highlighted Red Violet (RDVT) as an “underdog” with a CORE platform positioned as AI-powered yet not threatened by AI.
Ticker impact
Immersion’s Q2 2026 letter spotlights Red Violet’s CORE identity platform and cites expectation-beating Q2 results plus Forewarn’s healthcare entry.
Near-term price impact is likely limited unless traders treat the Forewarn healthcare entry and revenue opportunity range as fresh, tradable catalysts.
RDVT is the title subject and the body includes concrete items (CORE positioning, Q1 revenue +17% YoY, Forewarn healthcare entry, and an addressable revenue range). However, the piece is primarily promotional/interpretive around results and does not provide new audited guidance or a clearly dated primary disclosure beyond the stated rollout.
Market effects
Supports the identity/risk-data software theme that non-AI-native identity intelligence can benefit from AI-era data security and compliance needs.
No clear regional spillover beyond US small-cap sentiment.
Limited, as the described opportunity is tied to US healthcare and identity data workflows.
Counterpoint
The “AI not exposed to AI threats” thesis may be overstated; customers could still shift budgets toward broader AI-enabled identity solutions even if CORE is positioned as secure.
Key entities
- public_companyRed Violet, Inc.
NASDAQ-listed identity intelligence and risk management software/services provider discussed as the article’s core subject.
- productForewarn
A consumer-facing application skin on RDVT’s CORE platform, described as formally entering healthcare.
- investment_firmImmersion Investment Partners
The investor-letter publisher providing the bullish thesis and performance framing.
